Clinical Trial Update: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ASP-1929 photoimmunotherapy in combination with pembrolizumab as first-line treatment for locoregionally recurrent head and neck squamo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ASP-1929
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Rakuten Medical, Inc. | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING